A5060121345- Parkinson's Disease Mechanisms and Treatments
- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Neurological disorders and treatments
- Anesthesia and Pain Management
- Genetic Neurodegenerative Diseases
- Anesthesia and Sedative Agents
- Cardiac, Anesthesia and Surgical Outcomes
- Pain Management and Opioid Use
- Neuroinflammation and Neurodegeneration Mechanisms
- Botulinum Toxin and Related Neurological Disorders
- Pediatric Pain Management Techniques
- Nausea and vomiting management
- Advanced Neuroimaging Techniques and Applications
- Blood Pressure and Hypertension Studies
- Poisoning and overdose treatments
- Neurological diseases and metabolism
- Opioid Use Disorder Treatment
- Epilepsy research and treatment
- Intensive Care Unit Cognitive Disorders
- Prion Diseases and Protein Misfolding
- Pain Mechanisms and Treatments
- Sodium Intake and Health
- Ginkgo biloba and Cashew Applications
- S100 Proteins and Annexins
University of Perugia
2006-2025
University of Milano-Bicocca
2020-2025
IRCCS Istituto Auxologico Italiano
2024
Martin Luther University Halle-Wittenberg
2023
Fondazione IRCCS Istituto Neurologico Carlo Besta
2022
Weatherford College
2020
China Rehabilitation Research Center
2019
Azienda Ospedaliera di Perugia
1987-2018
Ospedale Santa Maria
2018
Misericordia University
2006-2009
Abstract INTRODUCTION Lewy body disease, a frequently observed co‐pathology in Alzheimer's disease (AD), can be identified antemortem cerebrospinal fluid (CSF) by α‐synuclein seed amplification assay (αS‐SAA). The prevalence and clinical impact of CSF αS‐SAA positivity AD are still unknown. METHODS was performed on samples from 240 patients (preclinical, prodromal, dementia stages), 85 controls, 84 with Parkinson's (PD), 21 PD or bodies. In patients, associations between cognitive changes...
Abstract INTRODUCTION For routine clinical implementation of Alzheimer's disease (AD) plasma biomarkers, fully automated random‐access platforms are crucial to ensure reproducible measurements. We aimed perform an analytical validation and establish cutoffs for AD biomarkers measured with Lumipulse. METHODS Two cohorts were included. UNIPG: n = 450 paired cerebrospinal fluid (CSF)/plasma samples from subjects along the AD‐continuum, affected by other neurodegenerative diseases, controls...
Alzheimer's disease (AD) is the most frequent neurodegenerative disorder worldwide. The great variability in evolution and incomplete understanding of molecular mechanisms underlying AD make it difficult to predict when a patient will convert from prodromal stage dementia. We hypothesize that metabolic alterations present at level brain could be reflected systemic blood serum patients, these used as prognostic biomarkers. This pilot study proposes investigation via nuclear magnetic resonance...
Patients with Lewy body disease (LBD) often show a co-occurring Alzheimer (AD) pathology. CSF biomarkers allow the detection in vivo of AD-related pathologic hallmarks included amyloid-tau-neurodegeneration (AT(N)) classification system. Here, we aimed to investigate whether synaptic and neuroaxonal damage are correlated presence AD copathology LBD can be useful differentiate patients different AT(N) profiles.
Abstract Levodopa-induced dyskinesias (LID) negatively impact on the quality of life patients with Parkinson’s disease (PD). We assessed risk factors for LID in a cohort de-novo PD enrolled Progression Markers Initiative (PPMI). This retrospective study included all PPMI cohort. Main outcome was incidence rate dyskinesia, defined as first time patient reported non-zero score item “Time spent dyskinesia” MDS-UPDRS part IV. Predictive value development clinical and demographical features,...
Abstract Introduction The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting results may differ, which can lead misunderstandings raises questions about commutability tests. Methods We obtained description (pre‐)analytical protocols sample reports 40 centers worldwide. A consensus approach allowed us propose harmonized comments...
Background: Treatment of herpes zoster (HZ) includes the use acyclovir with or without steroids. An alternative therapy is epidural administration local anesthetics This trial compared efficacy these two treatment regimens in prevention post‐herpetic neuralgia (PHN). Methods: Six hundred adults over 55 years age a rash less than 7 days duration, and severe pain due to HZ, were enrolled randomized receive either intravenous (10 mg/kg three times daily) for 9 days+prednisolone (60 mg per day...
Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer’s disease (AD). The use fully automated biomarker assays has been shown to reduce intra- inter-laboratory variability, which is a critical factor when defining cut-off values. calculation values often influenced by composition AD control groups. Indeed, clinically defined group may include patients affected other forms dementia, while...
Background: The differential diagnosis of frontotemporal dementia (FTD) is still a challenging task due to its symptomatic overlap with other neurological diseases and the lack biofluid-based biomarkers. Objective: To investigate diagnostic potential combination novel biomarkers in cerebrospinal fluid (CSF) blood. Methods: We included 135 patients from Center for Memory Disturbances, University Perugia, diagnoses FTD (n = 37), mild cognitive impairment Alzheimer’s disease (MCI-AD, n 47),...
Pathophysiological substrate(s) and progression of Parkinson's disease (PD) with mild cognitive impairment (PD-MCI) are still matter debate. Baseline cerebrospinal fluid (CSF) neurochemical profile changes after 2 years were investigated in a retrospective series PD-MCI (n = 48), cognitively normal PD (PD-CN, n 40), prodromal Alzheimer's (MCI-AD, 25) healthy individuals other neurological diseases (OND, 44). CSF biomarkers reflecting amyloidosis (Aβ42/40 ratio, sAPPα, sAPPβ), tauopathy...
Introduction β-synuclein (β-syn) is a presynaptic protein, whose cerebrospinal fluid (CSF) levels are increased in patients with Alzheimer’s diseases (AD) showing mild cognitive impairment (MCI) and dementia (dem). Here, we aimed to investigate CSF β-syn subjects at different AD stages, including preclinical (pre-AD), compare its behaviour another synaptic biomarker, α-synuclein (α-syn), two biomarkers of neuro-axonal damage, namely neurofilament light chain protein (NfL) total tau (t-tau)....
Synaptic dysfunction is a relevant feature of Alzheimer's disease (AD) and Parkinson's (PD) can be quantified through the measurement cerebrospinal fluid (CSF) synaptic markers, such as presynaptic proteins synaptosomal-associated protein 25 kDa (SNAP25) vesicle-associated membrane 2 (VAMP2). Plasma-based assays for markers are also emerging. In neurodegenerative diseases, directly driven by proteinopathies amyloidosis (A), tauopathy (T), α-synucleinopathy (S), which in turn detected via CSF...
Background Cerebrospinal fluid (CSF) α-synuclein seed amplification assay (αS-SAA) is a recognized biomarker of synucleinopathy. In Parkinson's disease (PD), its potential for predicting clinical outcome needs to be further assessed. Objective To evaluate the associations between and αS-SAA kinetic parameters in retrospective cohort PD patients, also investigating whether CSF total protein content influences such associations. Methods Study included cognitively unimpaired (PD-CN, n = 40),...